Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis via lncRNA ADPGK-AS1 downregulation.

Authors

Can Chen, Xiaofei Chen, Xilian Huang, Yaping Xie, Pengfei Shi, Shenxian Qian, Zhenzhen Chen

Published in

Journal of enzyme inhibition and medicinal chemistry. Volume 41. Issue 1. Pages 2674446. Epub Jun 15, 2026.

Abstract

Shikonin, a natural compound, exhibits antitumor effects in DLBCL, but its mechanism remains unclear. Shikonin's cytotoxicity in DLBCL cells was assessed by MTT assays. Ferroptosis and lipid peroxidation markers were analysed via flow cytometry and biochemical kits. Mechanisms were explored using gene knockdown/overexpression, dual-luciferase assays, RNA pull-down, proteomics, RIP, FISH, and ChIP. Key proteins and genes involved in ferritinophagy and ferroptosis were examined by Western blot, RT-qPCR, and immunofluorescence, with findings validated in a nude mouse xenograft model. Shikonin triggers ferritinophagy and ferroptosis by increasing iron accumulation and lipid peroxidation. LncRNA ADPGK-AS1 protects against ferroptosis by regulating MT2A via eIF4G1 interaction. Shikonin triggers ferritinophagy and ferroptosis by disrupting iron metabolism and redox balance. The eIF4G1-ADPGK-AS1/MT2A axis mitigates these effects, revealing shikonin's antitumor mechanism and therapeutic potential.

PMID:
42295078
Bibliographic data and abstract were imported from PubMed on 15 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.